Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.34 USD | +5.33% | +2.47% | -26.06% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Financials (USD)
Sales 2024 * | 398M | Sales 2025 * | 443M | Capitalization | 1.48B |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -3M | EV / Sales 2024 * | 3.15 x |
Net cash position 2024 * | 220M | Net cash position 2025 * | 267M | EV / Sales 2025 * | 2.73 x |
P/E ratio 2024 * |
-80.5
x | P/E ratio 2025 * |
-463
x | Employees | 815 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
Latest transcript on Veracyte, Inc.
1 day | +5.33% | ||
1 week | +2.47% | ||
Current month | -8.21% | ||
1 month | -8.21% | ||
3 months | -24.92% | ||
6 months | +3.14% | ||
Current year | -26.06% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Stapley
CEO | Chief Executive Officer | 54 | 21-05-31 |
Rebecca Chambers
DFI | Director of Finance/CFO | 46 | 21-07-18 |
Steven French
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Evan Jones
BRD | Director/Board Member | 67 | 08-01-31 |
Robert Epstein
CHM | Chairman | 69 | 15-01-11 |
Karin Eastham
BRD | Director/Board Member | 74 | 12-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 20.34 | +5.33% | 632,989 |
24-04-26 | 19.31 | -0.87% | 629,746 |
24-04-25 | 19.48 | -2.11% | 654,265 |
24-04-24 | 19.9 | +0.35% | 511,680 |
24-04-23 | 19.83 | -0.10% | 563,849 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.06% | 1.48B | |
-20.55% | 10.82B | |
+47.97% | 3.25B | |
-32.75% | 2.11B | |
-14.15% | 2.08B | |
+19.85% | 1.02B | |
-2.62% | 733M | |
-31.67% | 391M | |
-43.88% | 383M | |
+29.03% | 332M |
- Stock Market
- Equities
- VCYT Stock